Biogen Inc. (BIIB) News
Filter BIIB News Items
BIIB News Results
|Loading, please wait...|
BIIB News Highlights
- BIIB's 30 day story count now stands at 102.
- Over the past 25 days, the trend for BIIB's stories per day has been choppy and unclear. It has oscillated between 1 and 14.
- The most mentioned tickers in articles about BIIB are DRUG, LAW and SAGE.
Latest BIIB News From Around the Web
Below are the latest news stories about Biogen Inc that investors may wish to consider to help them evaluate BIIB as an investment opportunity.
Teaser: Ionis (IONS) beats Q4 earnings and sales estimates. Stock rises.
The topic is much more exciting — and frightening — in the wake of Aduhelm, a drug developed by Biogen (BIIB) to treat early-stage Alzheimer’s disease with an original ask price of $56,000 per patient per year. Traditional Medicare is composed of two programs (see Table 1).
The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics
Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics are included in this blog.
Will Aduhelm''s controversial approval signal a new normal for clinical trials?
The Law Offices of Vincent Wong Remind Biogen Investors of a Lead Plaintiff Deadline of April 8, 2022
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between June 7, 2021 and January 11, 2022. If you suffered a loss on your investment in Biogen, contact us about potential recovery by using 
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against New Oriental Education, Biogen, Telos, and Fennec and Encourages Investors to Contact the Firm
NEW YORK, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of New Oriental Education & Technology Group, Inc. (NYSE: EDU), Biogen, Inc. (NASDAQ: BIIB), Telos Corporation (NASDAQ: TLS), and Fennec Pharmaceuticals, Inc. (NASDAQ: FENC). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
The approval was controversial, as some argued Biogen's clinical trials failed to prove the treatment's efficacy. In this video clip from "The Pharma & Biotech Show," recorded on Feb. 9, Motley Fool contributor Taylor Carmichael asks Dr. Frank David, author of , about what Biogen's drug approval means for investors and other biopharma companies.
Shares of Swiss pharma giant Roche (RHHBY) (RHHBF) had been weak going into earnings, and a 2H/Q4’21 earnings report that included some notable margin shortfalls certainly didn’t help matters, and neither did guidance that suggested only low-single-digit growth prospects in the near term. With that, shares of the ADRs are...
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firms Attorneys, Securities Class Action Filed
SAN FRANCISCO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Biogen Inc. (NASDAQ: BIIB) investors with significant losses to submit your losses now . A securities fraud class action has been filed and certain investors may have valuable claims.
Biogen (BIIB) had a disappointing performance recently, losing 35% over the last six months, in line with the healthcare sector. Biogen is a drugmaker working on innovative therapies to treat people with serious neurological diseases such as multiple sclerosis and Alzheimer's. The study of potential factors that trigger cognitive impairment has led to some scientific breakthroughs that could bring a breath of fresh air to Biogen's portfolio, as its treatments seem a little lazy from a profitability standpoint. This leads to a hopeful bullish stance on this stock.